AWS
IPXL

AJ Wealth Strategies’s Impax Laboratories, Inc. IPXL Stock Holding History

AJ Wealth Strategies’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,000
Closed -$161K – 81
2017
Q2 		$161K Buy
+10,000
New +$148K 0.06% 70

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

AJ Wealth Strategies's IPXL Position: Q3 2017 in Review

AJ Wealth Strategies sold out of Impax Laboratories, Inc. (IPXL) in Q3 2017, closing a stake of 10,000 shares — an estimated $161K sold.

AJ Wealth Strategies first reported a position in IPXL in Q2 2017 and held it in 1 quarter. The position peaked at $161K in Q2 2017. 189 funds tracked by Wall St. Rank hold IPXL as of Q3 2017.

  • AJ Wealth Strategies reported no remaining Impax Laboratories, Inc. position as of Q3 2017 after selling out during the quarter.
  • AJ Wealth Strategies sold 10,000 Impax Laboratories, Inc. shares in Q3 2017, an estimated $161K.
  • AJ Wealth Strategies first reported a position in Impax Laboratories, Inc. in Q2 2017 and held it in 1 quarter.
  • AJ Wealth Strategies's Impax Laboratories, Inc. position peaked at $161K in Q2 2017.
  • 189 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2017.

Based on AJ Wealth Strategies's 13F filing for Q3 2017, filed 19 Jul 2018.